CSB
MACK

City State Bank’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

City State Bank’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25
Closed – – 713
2022
Q3 		$0 Hold
25
– – ﹤0.01% 720
2022
Q2 		$0 Buy
+25
New +$141 ﹤0.01% 720

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

City State Bank's MACK Position: Q4 2022 in Review

City State Bank sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2022, closing a stake of 25 shares.

City State Bank first reported a position in MACK in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 47 funds tracked by Wall St. Rank hold MACK as of Q4 2022.

  • City State Bank reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • City State Bank sold 25 Merrimack Pharmaceuticals, Inc. shares in Q4 2022.
  • City State Bank first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2022 and held it in 2 quarters.
  • City State Bank's Merrimack Pharmaceuticals, Inc. position peaked at $0 in Q3 2022.
  • 47 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2022.

Based on City State Bank's 13F filing for Q4 2022, filed 12 Jan 2023.